Rodent tests for psychiatric drugs get a rethink

Sara Reardon

DOI: https://doi.org/10.1126/science.adp3269

IF: 56.9

2024-03-22

Science

Abstract:Under pressure to ditch a controversial swim test for depression, scientists look for more precise measures

multidisciplinary sciences

What problem does this paper attempt to address?

Rodent Models of Depression: Forced Swim and Tail Suspension Behavioral Despair Tests in Rats and Mice

Vincent Castagné,Paul Moser,Sylvain Roux,Roger D. Porsolt

DOI: https://doi.org/10.1002/0471142301.ns0810as55

2011-04-01

Current Protocols in Neuroscience

Abstract:The development of antidepressants requires simple rodent behavioral tests for initial screening before undertaking more complex preclinical tests and clinical evaluation. Presented in the unit are two widely used screening tests used for antidepressants, the forced swim (also termed behavioral despair) test in the rat and mouse, and the tail suspension test in the mouse. These tests have good predictive validity and allow rapid and economical detection of substances with potential antidepressant-like activity. The behavioral despair and the tail suspension tests are based on the same principle: measurement of the duration of immobility when rodents are exposed to an inescapable situation. The majority of clinically used antidepressants decrease the duration of immobility. Antidepressants also increase the latency to immobility, and this additional measure can increase the sensitivity of the behavioral despair test in the mouse for certain classes of antidepressant. Testing of new substances in the behavioral despair and tail suspension tests allows a simple assessment of their potential antidepressant activity by the measurement of their effect on immobility.
Using tests and models to assess antidepressant-like activity in rodents

Ewa Kedzierska,Izabela Wach

DOI: https://doi.org/10.1515/cipms-2016-0013

2016-06-01

Current Issues in Pharmacy and Medical Sciences

Abstract:Abstract In today's world, depression is one of the more prevalent forms of mental illness. According to WHO, about 10%-30% of all women and 7%-15% of all men are afflicted by depression at least once in their life-times. Today, depression is assessed to be affecting 350 million people. Regarding this issue, an important challenge for current psychopharmacology is to develop new, more effective pharmacotherapy and to understand the mechanism of action of known antidepressants. Furthermore, there is the necessity to improve the effectiveness of anti-depression treatment by way of bringing about an understanding of the neurobiology of this illness. In achieving these objectives, animal models of depression can be useful. Yet, presently, all available animal models of depression rely on two principles: the actions of known antidepressants or the responses to stress. In this paper, we present an overview of the most widely used animal tests and models that are employed in assessing antidepressant-like activity in rodents. These include amphetamine potentiation, reversal of reserpine action, the forced swimming test, the tail suspension test, learned helplessness, chronic mild stress and social defeat stress. Moreover, the advantages and major drawbacks of each model are also discussed.
A translational rodent assay of affective biases in depression and antidepressant therapy

Sarah A Stuart,Paul Butler,Marcus R Munafò,David J Nutt,Emma Sj Robinson

DOI: https://doi.org/10.1038/npp.2013.69

Neuropsychopharmacology

Abstract:The subjective measures used to study mood disorders in humans cannot be replicated in animals; however, the increasing application of objective neuropsychological methods provides opportunities to develop translational animal tasks. Here we describe a novel behavioral approach, which has enabled us to investigate similar affective biases in rodents. In our affective bias test (ABT), rats encounter two independent positive experiences--the association between food reward and specific digging substrate--during discrimination learning sessions. These are performed on separate days under either neutral conditions or during a pharmacological or affective state manipulation. Affective bias is then quantified using a preference test where both previously rewarded substrates are presented together and the rat's choices recorded. The absolute value of the experience is kept consistent and all other factors are counterbalanced so that any bias at recall can be attributed to treatment. Replicating previous findings from studies in healthy volunteers, we observe significant positive affective biases following acute treatment with typical (fluoxetine, citalopram, reboxetine, venlafaxine, clomipramine) and atypical antidepressants (agomelatine, mirtazapine), and significant negative affective biases following treatment with drugs associated with inducing negative affective states in humans (FG7142, rimonabant, 13-cis retinoic acid). We also observed that acute psychosocial stress and environmental enrichment induce significant negative and positive affective biases, respectively, and provide evidence that these affective biases involve memory consolidation. The positive and negative affective biases induced in our test also mirror the antidepressant and pro-depressant effects of these drugs in patients suggesting our test has both translational and predictive validity. Our results suggest that cognitive affective biases could contribute to drug- or stress-induced mood changes in people and support the hypothesis that a cognitive neuropsychological mechanism contributes to antidepressant drug efficacy.
The need for guidance in antidepressant drug development: Revisiting the role of the forced swim test and tail suspension test

Emily R Trunnell,Julia Baines,Stephen Farghali,Tara Jackson,Kimberley Jayne,Rachel Smith,Tina Stibbe

DOI: https://doi.org/10.1016/j.yrtph.2024.105666

Abstract:Depressive disorders are one of the most common mental disorders globally and progress in treating these disorders has been hampered, in part, by a lack of suitable nonclinical efficacy tests. Two common tests used in nonclinical efficacy studies of antidepressants-the forced swim test (FST) and tail suspension test (TST)-have come under criticism in recent years for their inconsistency and lack of validity, yet they continue to be used in the pharmaceutical industry. In this review, we provide a rationale for why international pharmaceutical regulatory and guidance agencies should begin issuing direction on methods for non-clinical efficacy testing that traditionally use the FST and TST, particularly considering that some regulators, such as those in the U.S. and E.U., allow the authorization of clinical trials to proceed without requiring tests in animals. The area of antidepressant drug discovery represents an important opportunity for reducing the attrition of psychiatric drugs, harmonizing regulatory requirements, and reducing animal use. Specific recommendations for the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) have been provided.
Rodent tests of depression and anxiety: Construct validity and translational relevance

Sinem Gencturk,Gunes Unal

DOI: https://doi.org/10.3758/s13415-024-01171-2

2024-02-28

Cognitive Affective & Behavioral Neuroscience

Abstract:Behavioral testing constitutes the primary method to measure the emotional states of nonhuman animals in preclinical research. Emerging as the characteristic tool of the behaviorist school of psychology, behavioral testing of animals, particularly rodents, is employed to understand the complex cognitive and affective symptoms of neuropsychiatric disorders. Following the symptom-based diagnosis model of the DSM, rodent models and tests of depression and anxiety focus on behavioral patterns that resemble the superficial symptoms of these disorders. While these practices provided researchers with a platform to screen novel antidepressant and anxiolytic drug candidates, their construct validity—involving relevant underlying mechanisms—has been questioned. In this review, we present the laboratory procedures used to assess depressive- and anxiety-like behaviors in rats and mice. These include constructs that rely on stress-triggered responses, such as behavioral despair, and those that emerge with nonaversive training, such as cognitive bias. We describe the specific behavioral tests that are used to assess these constructs and discuss the criticisms on their theoretical background. We review specific concerns about the construct validity and translational relevance of individual behavioral tests, outline the limitations of the traditional, symptom-based interpretation, and introduce novel, ethologically relevant frameworks that emphasize simple behavioral patterns. Finally, we explore behavioral monitoring and morphological analysis methods that can be integrated into behavioral testing and discuss how they can enhance the construct validity of these tests.

behavioral sciences,neurosciences
Effects of cognitive judgement bias and acute antidepressant treatment on sensitivity to feedback and cognitive flexibility in the rat version of the probabilistic reversal-learning test

Robert Drozd,Michal Rychlik,Agata Fijalkowska,Rafal Rygula

DOI: https://doi.org/10.1016/j.bbr.2018.10.003

2019-02-01

Abstract:Depressive disorders are often associated with cognitive biases. In this study, we investigated, in an animal model, whether cognitive judgement bias, measured as a stable and enduring behavioural trait, could modulate the effects of antidepressant drugs on other cognitive processes associated with depression. For this purpose, we identified rats displaying 'pessimistic' and 'optimistic' traits in a series of ambiguous-cue interpretation (ACI) tests. Subsequently, in the preclinical version of the probabilistic reversal-learning (PRL) test, allowing multiple reversals within a test session, we compared the effects of acute administration of 5 different antidepressant (AD) drugs (agomelatine, escitalopram, clomipramine, mirtazapine and venlafaxine) on cognitive flexibility and sensitivity to positive/negative feedback in optimistic and pessimistic animals. We report that, following acute treatment with agomelatine, the proportion of lose-shift behaviours in the PRL test was significantly reduced in pessimistic animals compared to optimists. We also demonstrate that acute treatment with another antidepressant drug, mirtazapine, significantly increased the sensitivity of rats to positive feedback, as indexed by the increased proportion of win-stay behaviour following probabilistic reward. This effect was independent of cognitive bias and was associated with a reduced number of reversals made by the animals. Three other tested drugs had no significant effects on behavioural measures assessed in our study.
Forced swimming test in mice: a review of antidepressant activity

Benoit Petit-Demouliere,Franck Chenu,Michel Bourin

DOI: https://doi.org/10.1007/s00213-004-2048-7

2004-11-18

Psychopharmacology

Abstract:RationaleAmong all animal models, the forced swimming test (FST) remains one of the most used tools for screening antidepressants.ObjectiveThis paper reviews some of the main aspects of the FST in mice. Most of the sensitivity and variability factors that were assessed on the FST are summarized.MechanismsWe have summarized data found in the literature of antidepressant effects on the FST in mice. From this data set, we have extrapolated information on baseline levels of strain, and sensitivity against antidepressants.ResultsWe have shown that many parameters have to be considered in this test to gain good reliability. Moreover, there was a fundamental inter-strain difference of response in the FST.ConclusionsThe FST is a good screening tool with good reliability and predictive validity. Strain is one of the most important parameters to consider. Swiss and NMRI mice can be used to discriminate the mechanisms of action of drugs. CD-1 seems to be the most useful strain for screening purposes, but this needs to be confirmed with some spontaneous locomotor activity studies.

pharmacology & pharmacy,neurosciences,psychiatry
Rodent Models of Depression: Reexamining Validity Without Anthropomorphic Inference

Philip V Holmes,Philip V. Holmes

DOI: https://doi.org/10.1615/critrevneurobiol.v15.i2.30

2003-01-01

Critical Reviews in Neurobiology

Abstract:This review aims to stimulate new ways of thinking about how to model depression in rats and mice. The article is founded on the premise that anthropomorphic inferences should be removed entirely from research involving rodents. The application of animal models to study depression over the past 30 years has been based largely on nonempirical and hence nonscientific assumptions about psychological states that probably do not exist and certainly cannot be measured in rodents. Such assumptions may have led to the misinterpretation of some behaviors, such as decreased locomotor activity or decreased sucrose consumption, as symptoms of depression in rats. Previous research has also overemphasized the causal role of stress in depression. After reviewing major features of several commonly employed models, this article challenges traditional concepts about validity. Models are first evaluated based on the goals of the research. Screening for potential antidepressant compounds requires little or no consideration of the validity of the model. Issues of validity become more critical when attempting to study the neurobiological basis of depression. The primary importance of face validity is emphasized, and the value of various behavioral measures is assessed based on how directly they resemble discrete behavioral symptoms seen in depressed humans. A "neurobehaviorally mechanistic" approach is described. This approach relies on formulating discrete, neurobiological hypotheses to explain individual symptoms rather than to explain collections of symptoms or the entire disorder. The approach thus relies on pragmatic measures of operationally well-defined behavioral variables. The review concludes with the proposal that understanding the neurobiological basis for individual symptoms will ultimately yield a better understanding of depression.
Depression: a new animal model sensitive to antidepressant treatments

R. D. PORSOLT,M. LE PICHON,M. JALFRE

DOI: https://doi.org/10.1038/266730a0

IF: 64.8

1977-04-01

Nature

Abstract:A MAJOR problem in the search for new antidepressant drugs is the lack of animal models which both resemble depressive illness and are selectively sensitive to clinically effective antidepressant treatments. We have been working on a new behavioural model in the rat which attempts to meet these two requirements. The method is based on the observation that a rat, when forced to swim in a situation from which there is no escape, will, after an initial period of vigorous activity, eventually cease to move altogether making only those movements necessary to keep its head above water. We think that this characteristic and readily identifiable behavioural immobility indicates a state of despair in which the rat has learned that escape is impossible and resigns itself to the experimental conditions. This hypothesis receives support from results presented below which indicate that immobility is reduced by different treatments known to be therapeutic in depression including three drugs, iprindole, mianserin and viloxazine which although clinically active1–3 show little or no ‘antidepressant’ activity in the usual animal tests4–6.

multidisciplinary sciences
The Rodent Forced Swim Test Measures Stress-Coping Strategy, Not Depression-like Behavior

Kathryn G Commons,Aram B Cholanians,Jessica A Babb,Daniel G Ehlinger

DOI: https://doi.org/10.1021/acschemneuro.7b00042

2017-05-17

Abstract:The forced swim test (FST) measures coping strategy to an acute inescapable stress and thus provides unique insight into the neural limb of the stress response. Stress, particularly chronic stress, is a contributing factor to depression in humans and depression is associated with altered response to stress. In addition, drugs that are effective antidepressants in humans typically promote active coping strategy in the FST. As a consequence, passive coping in the FST has become loosely equated with depression and is often referred to as "depression-like" behavior. This terminology oversimplifies complex biology and misrepresents both the utility and limitations of the FST. The FST provides little construct- or face-validity to support an interpretation as "depression-like" behavior. While stress coping and the FST are arguably relevant to depression, there are likely many factors that can influence stress coping strategy. Importantly, there are other neuropsychiatric disorders characterized by altered responses to stress and difficulty in adapting to change. One of these is autism spectrum disorder (ASD), and several mouse genetic models of ASD exhibit altered stress-coping strategies in the FST. Here we review evidence that argues a more thoughtful consideration of the FST, and more precise terminology, would benefit the study of stress and disorders characterized by altered response to stress, which include but are not limited to depression.
Structured evaluation of rodent behavioral tests used in drug discovery research

Anders Hånell,Niklas Marklund,Anders HÃ¥nell

DOI: https://doi.org/10.3389/fnbeh.2014.00252

IF: 3.617

2014-07-22

Frontiers in Behavioral Neuroscience

Abstract:A large variety of rodent behavioral tests are currently being used to evaluate traits such as sensory-motor function, social interactions, anxiety-like and depressive-like behavior, substance dependence and various forms of cognitive function. Most behavioral tests have an inherent complexity, and their use requires consideration of several aspects such as the source of motivation in the test, the interaction between experimenter and animal, sources of variability, the sensory modality required by the animal to solve the task as well as costs and required work effort. Of particular importance is a test's validity because of its influence on the chance of successful translation of preclinical results to clinical settings. High validity may, however, have to be balanced against practical constraints and there are no behavioral tests with optimal characteristics. The design and development of new behavioral tests is therefore an ongoing effort and there are now well over one hundred tests described in the contemporary literature. Some of them are well established following extensive use, while others are novel and still unproven. The task of choosing a behavioral test for a particular project may therefore be daunting and the aim of the present review is to provide a structured way to evaluate rodent behavioral tests aimed at drug discovery research.

behavioral sciences,neurosciences
The NEWMEDS Rodent Touchscreen Test Battery for Cognition Relevant to Schizophrenia

M. Hvoslef-Eide,A. C. Mar,S. R. O. Nilsson,J. Alsiö,C. J. Heath,L. M. Saksida,T. W. Robbins,T. J. Bussey

DOI: https://doi.org/10.1007/s00213-015-4007-x

2015-01-01

Psychopharmacology

Abstract:The NEWMEDS initiative (Novel Methods leading to New Medications in Depression and Schizophrenia, http://www.newmeds-europe.com ) is a large industrial-academic collaborative project aimed at developing new methods for drug discovery for schizophrenia. As part of this project, Work package 2 (WP02) has developed and validated a comprehensive battery of novel touchscreen tasks for rats and mice for assessing cognitive domains relevant to schizophrenia.This article provides a review of the touchscreen battery of tasks for rats and mice for assessing cognitive domains relevant to schizophrenia and highlights validation data presented in several primary articles in this issue and elsewhere.The battery consists of the five-choice serial reaction time task and a novel rodent continuous performance task for measuring attention, a three-stimulus visual reversal and the serial visual reversal task for measuring cognitive flexibility, novel non-matching to sample-based tasks for measuring spatial working memory and paired-associates learning for measuring long-term memory.The rodent (i.e. both rats and mice) touchscreen operant chamber and battery has high translational value across species due to its emphasis on construct as well as face validity. In addition, it offers cognitive profiling of models of diseases with cognitive symptoms (not limited to schizophrenia) through a battery approach, whereby multiple cognitive constructs can be measured using the same apparatus, enabling comparisons of performance across tasks.This battery of tests constitutes an extensive tool package for both model characterisation and pre-clinical drug discovery.
Effect size, sample size and power of forced swim test assays in mice: Guidelines for investigators to optimize reproducibility

Neil R. Smalheiser,Elena E. Graetz,Zhou Yu,Jing Wang

DOI: https://doi.org/10.1371/journal.pone.0243668

IF: 3.7

2021-02-24

PLoS ONE

Abstract:A recent flood of publications has documented serious problems in scientific reproducibility, power, and reporting of biomedical articles, yet scientists persist in their usual practices. Why? We examined a popular and important preclinical assay, the Forced Swim Test (FST) in mice used to test putative antidepressants. Whether the mice were assayed in a naïve state vs. in a model of depression or stress, and whether the mice were given test agents vs. known antidepressants regarded as positive controls, the mean effect sizes seen in the experiments were indeed extremely large (1.5–2.5 in Cohen’s d units); most of the experiments utilized 7–10 animals per group which did have adequate power to reliably detect effects of this magnitude. We propose that this may at least partially explain why investigators using the FST do not perceive intuitively that their experimental designs fall short—even though proper prospective design would require ~21–26 animals per group to detect, at a minimum, large effects (0.8 in Cohen’s d units) when the true effect of a test agent is unknown. Our data provide explicit parameters and guidance for investigators seeking to carry out prospective power estimation for the FST. More generally, altering the real-life behavior of scientists in planning their experiments may require developing educational tools that allow them to actively visualize the inter-relationships among effect size, sample size, statistical power, and replicability in a direct and intuitive manner.

multidisciplinary sciences
The future of rodent models in depression research

Anand Gururajan,Andreas Reif,John F. Cryan,David A. Slattery

DOI: https://doi.org/10.1038/s41583-019-0221-6

IF: 38.755

2019-10-02

Nature Reviews Neuroscience

Abstract:Currently, over 300 million people worldwide have depression, and the socioeconomic burden of this debilitating disorder is anticipated to increase markedly over the coming decades against a background of increasing global turmoil. Despite this impending crisis, we are still waiting for improved therapeutic options for this disorder to emerge, which has led to increasing criticism of the role and value of preclinical models of depression. In this Review, we examine this landscape, focusing firstly on issues related to the terminology used in this context and the myriad of preclinical approaches to modelling and assaying aspects of depression in rodents. We discuss the importance of sex as a biological variable and the controversial idea of intergenerational and transgenerational transmission of depressive-like traits. We then examine the technical strategies available to dissect these models and review emerging evidence for putative druggable disease mechanisms. Finally, we propose a brief framework for future research that makes optimal use of these models and will, we hope, accelerate the discovery of improved antidepressants.

neurosciences
A repeated measures cognitive affective bias test in rats: comparison with forced swim test

Benjamin Aliphon,Twain Dai,Jessica Moretti,Marissa Penrose-Menz,Wilhelmina H A M Mulders,Dominique Blache,Jennifer Rodger

DOI: https://doi.org/10.1007/s00213-022-06281-8

Abstract:Rationale: There is an urgent need to identify behaviours in animals that can provide insight into the aetiology and potential treatment of depression in humans. Objectives: This study aimed to validate a repeated measures cognitive affective bias (CAB) test in a rat model of chronic stress and compare CAB with forced swim test (FST) measures. Methods: Male and female Sprague Dawley rats were trained to associate large and small rewards with scent, spatial, and tactile cues, and their response to an ambiguous tactile stimulus tested. Rats underwent weekly CAB testing for 4 weeks with no intervention, or for 2 weeks of chronic restraint stress (CRS), followed by 2 weeks of fluoxetine, vehicle, or no treatment. CRS rats also underwent the FST at selected timepoints. Results: In control rats, CAB was positive and remained stable over the 4-week period. In CRS-fluoxetine and CRS-vehicle groups, CAB was initially positive, became negative during chronic restraint stress, and returned to positive by 2 weeks after treatment. However, in the CRS-no treatment group, CAB was variable at the outset and unstable over time. Behaviour in the FST was not affected by treatment, and there was no correlation between CAB and FST outcomes. Conclusions: Instability in the CRS-no treatment group precluded interpretation of the impact of fluoxetine on CAB post-CRS. Our results suggest that behaviour in the FST does not reflect or alter affective state and support the use of CAB tests as part of the behavioural testing repertoire for preclinical animal models of affective disorders.
Depression Assessment in Clinical Trials and Pre-clinical Tests: A Critical Review

Lígia Castanheira,Diogo Telles-Correia,Miguel F. Ferreira,Ana M. Sebastião

DOI: https://doi.org/10.2174/1568026618666181115095920

2018-12-21

Current Topics in Medicinal Chemistry

Abstract:Depression is deeply rooted in human behavior. The development of new antidepressants demands the creation of animal models to investigate new drugs, which potentially could work as antidepressants. The aim of this review is to discuss the different ways of assessing depression in clinical research, including clinical trials, and the different animal behavioral tests used to study depression and test the efficacy of antidepressants in pre-clinical studies. In clinical practice, a categorical classification, such as the Diagnostic and Statistical Manual of Mental Disorders (DSM) and the International Statistical Classification of Diseases and Related Health Problems (ICD) can be used for diagnosis, through the use of structured and semi-structured interviews. On the other hand, depression can also be assessed using a dimensional approach, through self- or clinicianrated questionnaires. Regarding the assessment of the efficacy of antidepressants in animal models, several tests are routinely used, namely the Forced Swim Test, the Modified Forced Swim Test, the Tail Suspension Test and the Sucrose Preference Test. These tests are informative, providing that the following rules are taken into account: 1) more than one test is used, with coherent results; 2) secondary drug effects, the most frequent being putative changes in motor activity, are taken into account and properly controlled with specific tests run concomitantly; 3) each test and specific protocol is validated with data from at least a gold standard antidepressant drug. We herein briefly discuss the potential and limitations of each of those tests.

chemistry, medicinal
Reserpine-induced rat model for depression: Behavioral, physiological and PET-based dopamine receptor availability validation

Lidia Miguel Telega,Raissa Berti,Ganna Blazhenets,Lisa-Charlotte Domogalla,Nils Steinacker,M. Aymen Omrane,Philipp T. Meyer,Volker A. Coenen,Ann-Christin Eder,Máté D. Döbrössy

DOI: https://doi.org/10.1016/j.pnpbp.2024.111013

IF: 5.201

2024-04-18

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Abstract:Background Reserpine (RES), a Vesicular Monoamine Transporter 2 (VMAT 2 ) inhibitor agent, has been used in preclinical research for many years to create animal models for depression and to test experimental antidepressant strategies. Nevertheless, evidence of the potential use and validity of RES as a chronic pharmacological model for depression is lacking, and there are no comprehensive studies of the behavioral effects in conjunction with molecular outcomes. Methods Experiment 1. Following baseline behavior testing sensitive to depression-like phenotype and locomotion (Phase 1), 27 Sprague-Dawley (SD) rats received i.p. either vehicle solution (0.0 mg/kg), low (0.2 mg/kg) or high (0.8 mg/kg) RES dose for 20 days using a pre-determined schedule and reassessed for behavioral phenotypes (Phase 2). After 10 days washout period, and a final behavioral assessment (Phase 3), the brains were collected 16 days after the last injection for mRNA-expression assessment. Experiment 2. In a similar timetable as in Experiment 1 but without the behavioral testing, 12 SD rats underwent repetitive dopamine D 2/3 receptor PET scanning with [ 18 F]DMFP following each Phase. The binding potential ( BP ND ) of [ 18 F]DMFP was quantified by kinetic analysis as a marker of striatal D 2/3 R availability. Weight and welfare were monitored throughout the study. Results Significant, dose-dependent weight loss and behavioral deficits including both motor (hypo-locomotion) and non-motor behavior (anhedonia, mild anxiety and reduced exploration) were found for both the low and high dose groups with significant decrease in D 2 R mRNA expression in the accumbal region for the low RES group after Phase 3. Both RES treated groups showed substantial increase in [ 18 F]DMFP BP ND (in line with dopamine depletion) during Phase 2 and 3 compared to baseline and Controls. Conclusions The longitudinal design of the study demonstrated that chronic RES administration induced striatal dopamine depletion that persisted even after the wash-out period. However, the behavior phenotype observed were transient. The data suggest that RES administration can induce a rodent model for depression with mild face validity.

pharmacology & pharmacy,neurosciences,psychiatry,clinical neurology
The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice

John F. Cryan,Cedric Mombereau,Annick Vassout

DOI: https://doi.org/10.1016/j.neubiorev.2005.03.009

2005-01-01

Abstract:Since its introduction almost 20 years ago, the tail suspension test has become one of the most widely used models for assessing antidepressant-like activity in mice. The test is based on the fact that animals subjected to the short-term, inescapable stress of being suspended by their tail, will develop an immobile posture. Various antidepressant medications reverse the immobility and promote the occurrence of escape-related behaviour. This review focuses on the utility this test as part of a research program aimed at understanding the mechanism of action of antidepressants. We discuss the inherent difficulties in modeling depression in rodents. We describe how the tail suspension differs from the closely related forced swim test. Further, we address some key issues associated with using the TST as a model of antidepressant action. We discuss issues regarding whether it satisfies criteria to be a valid model for assessing depression-related behavioural traits. We elaborate on the tests' ease of use, strain differences observed in the test and gender effects in the test. We focus on the utility of the test for genetic analysis. Furthermore, we discuss the concept of whether immobility maybe a behavioural trait relevant to depression. All of the available pharmacological data using the test in genetically modified mice is collated. Special attention is given to selective breeding programs such as the Rouen 'depressed' mice which have been bred for high and low immobility in the tail suspension test. We provide an extensive pooling of the pharmacological studies published to date using the test. Finally, we provide novel pharmacological validation of an automated system (Bioseb) for assessing immobility. Taken together, we conclude that the tail suspension test is a useful test for assessing the behavioural effects of antidepressant compounds and other pharmacological and genetic manipulations relevant to depression.

behavioral sciences,neurosciences
Profiling attention and cognition enhancing drugs in a rat touchscreen-based continuous performance test

Zhiyong Ding,Jordan W. Brown,Lynne E. Rueter,Eric G. Mohler

DOI: https://doi.org/10.1007/s00213-017-4827-y

2018-01-13

Psychopharmacology

Abstract:RationaleA novel rodent continuous performance test (CPT) was developed as one of the goals of the NEWMEDS (Novel Methods leading to New Medications in Depression and Schizophrenia) consortium to improve its translatability to the CPT test used in human subjects.ObjectivesThe objective of the study is to investigate the effects of attention and cognition enhancing drugs in rodent CPT.MethodsA single cohort of rats were trained to asymptotic performance in the test. Pharmacological test sessions were then performed twice per week in a full crossover design with the following drugs tested: methylphenidate (0.3, 1, and 3 mg/kg), the α4β2 nicotinic agonist ABT-594 (0.0023, 0.007 and 0.023 mg/kg), modafinil (8, 16, and 32 mg/kg), atomoxetine (0.3, 1, and 3 mg/kg), donepezil (0.1, 0.3, and 1 mg/kg), and memantine (1.25, 2.5, and 5 mg/kg).ResultsThe stimulant-like drugs methylphenidate, ABT-594, and modafinil were found to increase measures of impulsivity and overall responding with generally no positive effects on d’, a putative measure of attention, with the exception of ABT-594 which improved d’ at the highest dose tested. Atomoxetine and the memory-enhancing drugs donepezil and memantine, on the other hand, were found to reduce measures of impulsivity and responding and had either negligible or worsening effects on d’.ConclusionsOur results suggest rodent CPT can detect changes in impulsivity resulting from drugs known to improve attention in rodents and humans. However, additional work is needed to assess the sensitivity and validity of this assay for assessing effects on attention.

pharmacology & pharmacy,neurosciences,psychiatry
Corticolimbic Transcriptome Changes are State-Dependent and Region-Specific in a Rodent Model of Depression and of Antidepressant Reversal

Alexandre Surget,Yingjie Wang,Samuel Leman,Yadira Ibarguen-Vargas,Nicole Edgar,Guy Griebel,Catherine Belzung,Etienne Sibille

DOI: https://doi.org/10.1038/npp.2008.76

2008-06-04

Neuropsychopharmacology

Abstract:Gene microarrays may enable the elucidation of neurobiological changes underlying the pathophysiology and treatment of major depression. However, previous studies of antidepressant treatments were performed in healthy normal rather than ‘depressed’ animals. Since antidepressants are devoid of mood-changing effects in normal individuals, the clinically relevant rodent transcriptional changes could remain undetected. We investigated antidepressant-related transcriptome changes in a corticolimbic network of mood regulation in the context of the unpredictable chronic mild stress (UCMS), a naturalistic model of depression based on socio-environmental stressors. Mice subjected to a 7-week UCMS displayed a progressive coat state deterioration, reduced weight gain, and increased agonistic and emotion-related behaviors. Chronic administration of an effective (fluoxetine) or putative antidepressant (corticotropin-releasing factor-1 (CRF1) antagonist, SSR125543) reversed all physical and behavioral effects. Changes in gene expression differed among cingulate cortex (CC), amygdala (AMY) and dentate gyrus (DG) and were extensively reversed by both drugs in CC and AMY, and to a lesser extent in DG. Fluoxetine and SSR125543 also induced additional and very similar molecular profiles in UCMS-treated mice, but the effects of the same drug differed considerably between control and UCMS states. These studies established on a large-scale that the molecular impacts of antidepressants are region-specific and state-dependent, revealed common transcriptional changes downstream from different antidepressant treatments and supported CRF1 targeting as an effective therapeutic strategy. Correlations between UCMS, drug treatments, and gene expression suggest distinct AMY neuronal and oligodendrocyte molecular phenotypes as candidate systems for mood regulation and therapeutic interventions.

pharmacology & pharmacy,neurosciences,psychiatry

Rodent tests for psychiatric drugs get a rethink

Rodent Models of Depression: Forced Swim and Tail Suspension Behavioral Despair Tests in Rats and Mice

Using tests and models to assess antidepressant-like activity in rodents

A translational rodent assay of affective biases in depression and antidepressant therapy

The need for guidance in antidepressant drug development: Revisiting the role of the forced swim test and tail suspension test

Rodent tests of depression and anxiety: Construct validity and translational relevance

Effects of cognitive judgement bias and acute antidepressant treatment on sensitivity to feedback and cognitive flexibility in the rat version of the probabilistic reversal-learning test

Forced swimming test in mice: a review of antidepressant activity

Rodent Models of Depression: Reexamining Validity Without Anthropomorphic Inference

Depression: a new animal model sensitive to antidepressant treatments

The Rodent Forced Swim Test Measures Stress-Coping Strategy, Not Depression-like Behavior

Structured evaluation of rodent behavioral tests used in drug discovery research

The NEWMEDS Rodent Touchscreen Test Battery for Cognition Relevant to Schizophrenia

Effect size, sample size and power of forced swim test assays in mice: Guidelines for investigators to optimize reproducibility

The future of rodent models in depression research

A repeated measures cognitive affective bias test in rats: comparison with forced swim test

Depression Assessment in Clinical Trials and Pre-clinical Tests: A Critical Review

Reserpine-induced rat model for depression: Behavioral, physiological and PET-based dopamine receptor availability validation

The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice

Profiling attention and cognition enhancing drugs in a rat touchscreen-based continuous performance test

Corticolimbic Transcriptome Changes are State-Dependent and Region-Specific in a Rodent Model of Depression and of Antidepressant Reversal